Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Description

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Conditions

Multiple Myeloma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Condition
Multiple Myeloma
Intervention / Treatment

-

Contacts and Locations

Birmingham

Local Institution, Birmingham, Alabama, United States, 35213

Birmingham

Local Institution - 0021, Birmingham, Alabama, United States, 35243

Muscle Shoals

Local Institution - 0013, Muscle Shoals, Alabama, United States, 35661

Goodyear

Local Institute, Goodyear, Arizona, United States, 85338

Anaheim

Local Institution - 0023, Anaheim, California, United States, 92801

Anaheim

Local Institution, Anaheim, California, United States, 92801

Burbank

Local Institution - 0045, Burbank, California, United States, 91505

Corona

Local Institution, Corona, California, United States, 92880

Downey

Local Institution - 0048, Downey, California, United States, 90241

Fountain Valley

Local Institution - 0052, Fountain Valley, California, United States, 92708

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have documented progression from a prior LoT
  • * Participants who have initiated treatment with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent:
  • * IMiDs
  • * PIs
  • * Combination of IMiD + PI
  • * Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies)
  • * Eligible to receive frontline therapy for MM (no prior MM treatment)
  • * Participants who have initiated treatment for MM with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent:
  • * IMiDs
  • * PIs
  • * Combination of IMiD + PI
  • * Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies)
  • * Participants who are currently participating in a clinical trial for MM
  • * Participants who are currently receiving treatment for primary cancer other than MM
  • * Participants who are not willing or able to provide informed consent
  • * Participants who are incarcerated
  • * Participants under compulsory detention for treatment of a physical (eg, infectious) or psychiatric illness

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bristol-Myers Squibb,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2029-12-31